Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.33 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.31 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19660823 | 0.76 | MEN1 (0.30) | — | |
| SCHEMBL21347418 | 0.74 | MEN1 (0.31) | — | |
| SCHEMBL21137434 | 0.73 | ADORA2A (0.32) | CDK1CDK2CCNB1CCNE1 | |
| SCHEMBL22434688 | 0.71 | — | — | |
| SCHEMBL18416502 | 0.67 | — | — | |
| SCHEMBL21924557 | 0.57 | MEN1 (0.32) | — | |
| SCHEMBL23476158 | 0.56 | ADORA2A (0.33) | CDK1CDK2CCNB1CCNE1 | |
| SCHEMBL24499630 | 0.55 | ADORA2A (0.35) | CDK1CDK2CCNB1CCNE1 | |
| SCHEMBL18510350 | 0.55 | CDK1 (0.71) | CDK1CDK2CCNB1CCNE1CSNK1D | |
| SCHEMBL22326732 | 0.55 | ADORA2A (0.34) | CDK1CDK2CCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | CDK1 1534/4885CDK2 3858/4885CCNB1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.